Literature DB >> 34030964

Studying PAR-Dependent Chromatin Remodeling to Tackle PARPi Resistance.

Christina Andronikou1, Sven Rottenberg2.   

Abstract

Histone eviction and chromatin relaxation are important processes for efficient DNA repair. Poly(ADP) ribose (PAR) polymerase 1 (PARP1) is a key mediator of this process, and disruption of PARP1 activity has a direct impact on chromatin structure. PARP inhibitors (PARPis) have been established as a treatment for BRCA1- or BRCA2-deficient tumors. Unfortunately, PARPi resistance occurs in many patients and the underlying mechanisms are not fully understood. In particular, it remains unclear how chromatin remodelers and histone chaperones compensate for the loss of the PARylation signal. In this Opinion article, we summarize currently known mechanisms of PARPi resistance. We discuss how the study of PARP1-mediated chromatin remodeling may help in further understanding PARPi resistance and finding new therapeutic approaches to overcome it.
Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  DNA damage response; PARP inhibition; chromatin remodeling; drug resistance; poly(ADP) ribosylation polymerase

Mesh:

Substances:

Year:  2021        PMID: 34030964     DOI: 10.1016/j.molmed.2021.04.010

Source DB:  PubMed          Journal:  Trends Mol Med        ISSN: 1471-4914            Impact factor:   11.951


  6 in total

Review 1.  PARP1-modulated chromatin remodeling is a new target for cancer treatment.

Authors:  Saptarshi Sinha; Sefinew Molla; Chanakya Nath Kundu
Journal:  Med Oncol       Date:  2021-08-25       Impact factor: 3.064

2.  The Influence of PARP, ATR, CHK1 Inhibitors on Premature Mitotic Entry and Genomic Instability in High-Grade Serous BRCAMUT and BRCAWT Ovarian Cancer Cells.

Authors:  Patrycja Gralewska; Arkadiusz Gajek; Dorota Rybaczek; Agnieszka Marczak; Aneta Rogalska
Journal:  Cells       Date:  2022-06-10       Impact factor: 7.666

3.  Deubiquitination of FBP1 by USP7 blocks FBP1-DNMT1 interaction and decreases the sensitivity of pancreatic cancer cells to PARP inhibitors.

Authors:  Xiang Cheng; Bin Zhang; Feng Guo; Heshui Wu; Xin Jin
Journal:  Mol Oncol       Date:  2021-12-17       Impact factor: 6.603

Review 4.  PARP1: Liaison of Chromatin Remodeling and Transcription.

Authors:  Wen Zong; Yamin Gong; Wenli Sun; Tangliang Li; Zhao-Qi Wang
Journal:  Cancers (Basel)       Date:  2022-08-27       Impact factor: 6.575

Review 5.  Improving PARP inhibitor efficacy in high-grade serous ovarian carcinoma: A focus on the immune system.

Authors:  Nirashaa T Bound; Cassandra J Vandenberg; Apriliana E R Kartikasari; Magdalena Plebanski; Clare L Scott
Journal:  Front Genet       Date:  2022-09-09       Impact factor: 4.772

Review 6.  Is There a Role for Epigenetic Therapies in Modulating DNA Damage Repair Pathways to Enhance Chemotherapy and Overcome Drug Resistance?

Authors:  Ian Matthew Garner; Robert Brown
Journal:  Cancers (Basel)       Date:  2022-03-16       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.